Repligen Appoints Glenn P. Muir to Board of Directors
September 21 2015 - 8:46PM
Repligen Corporation (NASDAQ:RGEN) today announced that life
sciences industry veteran Glenn P. Muir has been elected to its
Board of Directors and appointed as a member of its Audit
Committee. Mr. Muir brings over 30 years of experience to the
director role, most recently as Chief Financial Officer and
Executive Vice President, Finance and Administration for Hologic,
Inc. (NASDAQ:HOLX), a large multi-national medical device and
diagnostics company where he was instrumental to the company’s
significant expansion.
“We are very pleased to welcome Mr. Muir as a member of our
Board,” said Tony J. Hunt, President and Chief Executive Officer of
Repligen. “Mr. Muir has been integral to the acquisition and
integration of over twenty companies and technologies. He
recognizes the importance of establishing technology leadership in
an evolving marketplace. As Repligen continues to grow and
diversify, we are confident that Mr. Muir’s experience will
contribute to the realization of our goal to be a best-in-class
bioprocessing company.”
Mr. Muir retired in May 2014 from Hologic, Inc., where he helped
steer the company’s evolution from a venture-backed single product
company to a publicly traded diversified organization with over
5,000 employees and $2.5 billion in revenue. He joined
Hologic in 1988 and served as CFO since 1992 and Executive Vice
President since 2000. Prior to Hologic, Mr. Muir was with Metallon
Engineered Materials Co., a private company where from 1986-1988 he
held the role of Vice President, Finance. Previously, from
1981-1984, he was a Senior Auditor with Arthur Andersen & Co.
Mr. Muir is a Certified Public Accountant with a Bachelors of
Business Administration from the University of Massachusetts,
Amherst. He also earned a Masters of Science from Bentley
University and a Masters of Business Administration from Harvard
University.
Currently, Mr. Muir also serves on the boards of medical device
company ReWalk Robotics Ltd. (NASDAQ:RWLK) and genomic tool company
RainDance Technologies, Inc. His previous board memberships include
Hologic, Inc. and airline inspection system company Vivid
Technologies, Inc. In 2011, Mr. Muir was named “CFO of the Year” by
Boston Business Journal and in 2009, he was recognized by
Institutional Investor as one of “America’s Best CFOs”.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company
focused on the development and commercialization of high-value
consumable products used in the process of manufacturing biological
drugs. Our bioprocessing products are sold to major life sciences
and biopharmaceutical companies worldwide. We are the leading
manufacturer of Protein A affinity ligands, a critical component of
Protein A media that is used to separate and purify monoclonal
antibody therapeutics. Our ATF System and our growth factor
products are used to increase product yield during the fermentation
stage of biologic drug manufacturing. In addition, we developed and
market an innovative line of “ready-to-use” chromatography columns
under our OPUS® brand that we deliver pre-packed with our
customers’ choice of purification media. Repligen’s corporate
headquarters are in Waltham, MA (USA) and our manufacturing
facilities are located in Waltham, MA and Lund, Sweden.
This press release may contain forward-looking statements within
the meaning of the federal securities laws. Investors are cautioned
that statements in this press release which are not strictly
historical statements including, without limitation, statements
identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” or “could” and similar expressions, constitute
forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including risks discussed from time to time in our filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update any forward-looking statements, except as
required by law.
Repligen Corporation
Sondra Newman
Senior Director Investor Relations
(781) 419-1881
snewman@repligen.com
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Apr 2023 to Apr 2024